

NoÃ©mie Jourde-Chiche

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2067067/publications.pdf>

Version: 2024-02-01

80
papers

3,514
citations

201674

27
h-index

149698

56
g-index

96
all docs

96
docs citations

96
times ranked

4849
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Bartonella and Coxiella</i> infections presenting as systemic vasculitis: case series and review of literature. <i>Rheumatology</i> , 2022, 61, 2609-2618.	1.9	15
2	Clinical phenotype and cytokine profile of adult IgA vasculitis with joint involvement. <i>Clinical Rheumatology</i> , 2022, 41, 1483-1491.	2.2	6
3	Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 628-637.	6.1	24
4	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis. <i>Presse Medicale</i> , 2022, 51, 104107.	1.9	2
5	Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. <i>BMC Nephrology</i> , 2022, 23, 67.	1.8	3
6	R�le du compl�ment dans la n�phropathie lupique et la n�phropathie du syndrome des anti-phospholipides. <i>La Presse M�dicale Formation</i> , 2022, 3, 156-156.	0.1	0
7	Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1747-1754.	2.9	10
8	Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. <i>Kidney International</i> , 2022, 102, 904-916.	5.2	12
9	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1420-1427.	0.9	24
10	Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
11	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA Network Open</i> , 2022, 5, e2220925.	5.9	18
12	Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1664-1674.	0.7	41
13	Should the Biopsychosocial Model Be Considered in Systemic Autoimmune Diseases? Comment on the Article by Posada et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 717-718.	5.6	3
14	IgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients. <i>Journal of Rheumatology</i> , 2021, 48, 735-740.	2.0	7
15	Impact of aging on phenotype and prognosis in IgA vasculitis. <i>Rheumatology</i> , 2021, 60, 4245-4251.	1.9	9
16	Diagnostic performance of pulmonary ultrasonography and a clinical score for the evaluation of fluid overload in haemodialysis patients. <i>Nephrologie Et Therapeutique</i> , 2021, 17, 42-49.	0.5	3
17	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. <i>Kidney International Reports</i> , 2021, 6, 746-754.	0.8	8
18	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 339-346.	3.4	22

#	ARTICLE	IF	CITATIONS
19	Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice. <i>Hypertension</i> , 2021, 77, 1260-1272.	2.7	2
20	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1690.	2.4	10
21	Unsupervised clustering analysis of data from an online community to identify lupus patient profiles with regards to treatment preferences. <i>Lupus</i> , 2021, 30, 1837-1843.	1.6	8
22	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. <i>Nature Communications</i> , 2021, 12, 4385.	12.8	29
23	Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2239-2245.	2.9	12
24	Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys. <i>Kidney International Reports</i> , 2021, 6, 2134-2143.	0.8	4
25	Kidney biopsy in very elderly patients: indications, therapeutic impact and complications. <i>BMC Nephrology</i> , 2021, 22, 362.	1.8	2
26	Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1665-1675.	4.5	8
27	Paradoxical association between blood modular interferon signatures and quality of life in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 1975-1983.	1.9	10
28	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. <i>Arthritis Research and Therapy</i> , 2020, 22, 223.	3.5	18
29	Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. <i>BMC Nephrology</i> , 2020, 21, 260.	1.8	10
30	Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 878-888.	2.9	43
31	Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis. <i>Kidney International</i> , 2020, 97, 1102-1104.	5.2	12
32	P0360URINARY PEPTIDOMIC ANALYSIS IN PROLIFERATIVE VERSUS NON-PROLIFERATIVE LUPUS NEPHRITIS : RESULTS OF THE PEPTIDU-LUP STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
33	Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. <i>Rheumatology</i> , 2020, 59, 2970-2975.	1.9	7
34	Gastrointestinal involvement in adult IgA vasculitis (Henoch-Schönlein purpura): updated picture from a French multicentre and retrospective series of 260 cases. <i>Rheumatology</i> , 2020, 59, 3050-3057.	1.9	23
35	First phenotypic description of a female patient with c.610â€%T > C variant of GLA: a renal-predominant presentation of Fabry disease. <i>BMC Medical Genetics</i> , 2020, 21, 137.	2.1	1
36	Sera From Patients With Minimal Change Disease Increase Endothelial Permeability to Sodium. <i>Kidney International Reports</i> , 2020, 5, 1071-1075.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Serum GlycA Level Is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity. <i>Journal of Clinical Medicine</i> , 2020, 9, 970.	2.4	8
38	Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 964-972.	4.5	13
39	Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease. <i>Toxins</i> , 2019, 11, 578.	3.4	32
40	Atypical and secondary hemolytic uremic syndromes have a distinct presentation and a common genetic risk factors. <i>Kidney International</i> , 2019, 95, 1443-1452.	5.2	74
41	Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 298.	2.4	3
42	MYH9-related disorders display heterogeneous kidney involvement and outcome. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 494-502.	2.9	16
43	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. <i>Kidney International</i> , 2019, 95, 666-679.	5.2	68
44	Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation. <i>Journal of Immunology Research</i> , 2019, 2019, 1-14.	2.2	27
45	Endothelium structure and function in kidney health and disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 87-108.	9.6	292
46	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 403-412.	2.4	39
47	Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor- κ B signaling pathway in human endothelial cells. <i>Archives of Toxicology</i> , 2019, 93, 121-136.	4.2	43
48	Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. <i>Kidney International</i> , 2018, 93, 986-999.	5.2	79
49	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1143-1149.	0.9	219
50	Apheresis to treat systemic vasculitis. <i>Joint Bone Spine</i> , 2018, 85, 177-183.	1.6	12
51	Autoantibodies Targeting Ficolin-2 in Systemic Lupus Erythematosus Patients With Active Nephritis. <i>Arthritis Care and Research</i> , 2018, 70, 1263-1268.	3.4	14
52	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	5.8	62
53	Hemodialysis vascular graft as a focus of persistent Q fever. <i>Infection</i> , 2018, 46, 881-884.	4.7	8
54	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. <i>Frontiers in Immunology</i> , 2018, 9, 2260.	4.8	42

#	ARTICLE	IF	CITATIONS
55	Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 906-918.	6.1	21
56	Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. <i>Rheumatology</i> , 2017, 56, kew439.	1.9	34
57	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
58	Aphéses dans le traitement des vascularites systémiques. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 270-275.	0.0	1
59	Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. <i>Arthritis and Rheumatology</i> , 2017, 69, 1862-1870.	5.6	117
60	Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection. <i>Case Reports in Transplantation</i> , 2017, 2017, 1-7.	0.3	8
61	From BLISS to ILLUMINATE studies: ‘Blys repetita placent’: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e10-e10.	0.9	2
62	Introducing a New Dimension to Molecular Disease Classifications. <i>Trends in Molecular Medicine</i> , 2016, 22, 451-453.	6.7	7
63	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. <i>Medicine (United States)</i> , 2016, 95, e3748.	1.0	64
64	Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 431-441.	4.5	54
65	Acute pancreatitis as a cause of mortality in pediatric systemic lupus erythematosus: Results of a multiple cause-of-death analysis in France. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, e6-e7.	3.4	3
66	An interactive web application for the dissemination of human systems immunology data. <i>Journal of Translational Medicine</i> , 2015, 13, 196.	4.4	49
67	The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 876-887.	6.1	239
68	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. <i>Journal of Autoimmunity</i> , 2015, 65, 49-55.	6.5	34
69	The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty-Seven Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 527-534.	5.6	136
70	Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures. <i>Arthritis and Rheumatology</i> , 2014, 66, 1583-1595.	5.6	302
71	Mortality Associated With Systemic Lupus Erythematosus in France Assessed by Multiple-Cause-Of-Death Analysis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2503-2511.	5.6	152
72	Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. <i>Kidney International</i> , 2013, 84, 733-744.	5.2	205

#	ARTICLE	IF	CITATIONS
73	Disease Mechanisms in Rheumatologyâ€™Tools and Pathways: Current Perspectives on Systems Immunology Approaches to Rheumatic Diseases. Arthritis and Rheumatism, 2013, 65, 1407-1417.	6.7	21
74	Original Approach for Automated Quantification of Antinuclear Autoantibodies by Indirect Immunofluorescence. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	20
75	Association between anti-C1q antibodies and glomerular tuft necrosis in lupus nephritis. Clinical Nephrology, 2012, 77, 211-218.	0.7	11
76	Vascular Incompetence in Dialysis Patientsâ€™Proteinâ€™Bound Uremic Toxins and Endothelial Dysfunction. Seminars in Dialysis, 2011, 24, 327-337.	1.3	158
77	Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2281-2286.	2.3	63
78	Does Uremia Cause Vascular Dysfunction. Kidney and Blood Pressure Research, 2011, 34, 284-290.	2.0	122
79	PROGRESS IN UREMIC TOXIN RESEARCH: Proteinâ€™Bound Toxinsâ€™Update 2009. Seminars in Dialysis, 2009, 22, 334-339.	1.3	139
80	Reply to â€™Kidney involvement in hereditary transthyretin amyloidosis: is there a role for cystatin C?â€™. CKJ: Clinical Kidney Journal, 0, , .	2.9	1